Studies Confirm MIVT's HAp Total Biocompatibility Claims

MIV Therapeutics (MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has summarized the results of two independent Japanese studies that found strong blood compatibility, adsorption of proteins and overall biological safety of hydroxyapatite (HAp) in blood.

The two Japanese studies add independent substantiation to MIVT's own reports of exceptional biocompatibility and safety of the company's proprietary HAp-based coating technology for cardiovascular stents and medical devices. The studies found that HAp demonstrated exceptional performance and safety across several tested parameters in tests involving human blood samples, significantly bolstering and validating MIVT's proprietary technology and product development initiatives in multibillion-dollar markets for coronary stents and other medical devices, such as implantable drug-delivery systems.

MIVT has developed proprietary technology that uses HAp to create advanced biocompatible and drug-eluting coatings for cardiovascular stents and other implantable medical devices. MIVT's HAp technology is entering the final stages of evaluation in preparation for commercial introduction for use as an advanced coating for cardiovascular stents and other medical devices.